MiNK Therapeutics joins ARPA-H BoSS room-temperature cell therapy push
MiNK Therapeutics has been selected as a therapeutic cell platform partner within the Advanced Research Projects Agency for Health's BioStabilization Systems (BoSS) programme, a four-year, up to $87 million initiative targeting room-temperature storage and transport of living cell therapies. The New York-listed company's clinical-stage agenT-797 iNKT cell therapy will serve as one of the biological benchmarks against which the consortium's stabilisation technologies are validated.
MiNK joins the Reversible Ambient Biostabilization (RAB) team, led by The Charles Stark Draper Laboratory and including Likarda, CPSI Biotech, OFC Life Sciences, Case BioSciences, the University of Colorado Boulder, and Fresenius Kabi. The team will apply AI-assisted experimental design to optimise formulation conditions, hydrogel composition, quiescence induction, and recovery media, using a freeze-assisted droplet drying process to achieve a stable ambient product.
The cold-chain problem
Cold-chain logistics are widely regarded as one of the principal access barriers in allogeneic cell therapy. Most approved and investigational products require cryogenic storage near -196°C, limiting distribution to specialist centres with the necessary infrastructure. ARPA-H frames the BoSS programme as a "200-degree leap" toward storage near 21°C, a shift that, if achieved, would allow cell medicines to be stocked and shipped similarly to conventional biologics.
Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics, pointed to the company's existing logistical track record: "In our randomised Phase 2 trial in acute lung injury, we have already delivered agenT-797 to mechanically ventilated patients within days of regulatory authorisation, even in an active conflict zone." She added that removing cold-chain requirements could allow an iNKT therapy to be "stocked like a conventional drug and administered wherever critically ill patients present."
Nils Rudqvist, Senior Director of Research at MiNK, explained why iNKT cells represent a demanding test case for any stabilisation approach. Because iNKT cells activate within hours and coordinate both innate and adaptive immune responses, stabilisation technologies must preserve full functional activity rather than cell viability alone. The company also notes that iNKT cells do not require HLA matching, meaning a single manufacturing batch can supply a broad patient population.
Market context and competitive landscape
The broader allogeneic cell therapy sector has faced persistent commercial headwinds, with several earlier-generation programmes encountering efficacy limitations in pivotal trials. Room-temperature stability, if technically feasible at commercial scale, would represent a meaningful differentiator and could lower cost-of-goods substantially, a pressure point that has weighed on the economics of autologous and allogeneic approaches alike. Government-backed programmes such as BoSS carry reputational and technical validation value for participating companies, alongside the direct funding benefit.
MiNK's agenT-797 is in clinical development across solid tumours, graft-versus-host disease, and severe pulmonary immune failure. The BoSS collaboration does not alter the clinical timeline for any of these indications directly, but positions MiNK's manufacturing infrastructure as a reference system for the next generation of ambient-stable cell medicines. The company's next near-term milestones are data readouts from the ongoing Phase 2 acute lung injury study and further preclinical disclosure on its TCR-based and neoantigen-directed iNKT pipeline programmes.